- Home
- ELTK vs QNCX Comparison
ELTK vs QNCX Comparison
Compare ELTK & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELTK
- QNCX
- Stock Information
- Founded
- ELTK 1970
- QNCX 2012
- Country
- ELTK Israel
- QNCX United States
- Employees
- ELTK N/A
- QNCX N/A
- Industry
- ELTK Electrical Products
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ELTK Technology
- QNCX Health Care
- Exchange
- ELTK Nasdaq
- QNCX Nasdaq
- Market Cap
- ELTK 56.6M
- QNCX 44.0M
- IPO Year
- ELTK 1997
- QNCX 2019
- Fundamental
- Price
- ELTK $10.55
- QNCX $1.03
- Analyst Decision
- ELTK
- QNCX Strong Buy
- Analyst Count
- ELTK 0
- QNCX 5
- Target Price
- ELTK N/A
- QNCX $8.00
- AVG Volume (30 Days)
- ELTK 12.2K
- QNCX 511.8K
- Earning Date
- ELTK 05-20-2025
- QNCX 05-16-2025
- Dividend Yield
- ELTK 1.81%
- QNCX N/A
- EPS Growth
- ELTK N/A
- QNCX N/A
- EPS
- ELTK 0.63
- QNCX N/A
- Revenue
- ELTK $46,527,000.00
- QNCX N/A
- Revenue This Year
- ELTK $18.60
- QNCX N/A
- Revenue Next Year
- ELTK $9.04
- QNCX N/A
- P/E Ratio
- ELTK $15.86
- QNCX N/A
- Revenue Growth
- ELTK N/A
- QNCX N/A
- 52 Week Low
- ELTK $7.65
- QNCX $0.51
- 52 Week High
- ELTK $12.47
- QNCX $2.45
- Technical
- Relative Strength Index (RSI)
- ELTK 63.27
- QNCX 38.67
- Support Level
- ELTK $8.15
- QNCX $0.98
- Resistance Level
- ELTK $10.10
- QNCX $1.16
- Average True Range (ATR)
- ELTK 0.36
- QNCX 0.09
- MACD
- ELTK 0.21
- QNCX 0.01
- Stochastic Oscillator
- ELTK 75.49
- QNCX 22.22
About ELTK Eltek Ltd.
Eltek Ltd is engaged in the technology business sector that manufactures and supplies technologically new custom-made circuitry solutions. It manufactures, markets, and sells custom-made printed circuit boards (PCBs), including high-density interconnect, flex-rigid and multi-layered boards. The Company markets its products mainly to the medical technology, defense and aerospace, industrial, telecom, and networking equipment industries. Its geographic areas are Israel, North America, the Netherlands, India, and Others. It generates the majority of its revenue from Israel.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.